| Price | $47.14 |
| Year Range | $32.11 – $51.86 |
| Market Cap | $1.35B |
| PE Ratio | 24.29 |
| Industry | Medical Devices |
What Is Conmed’s AI Stock Analysis?
Conmed’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Conmed’s momentum in near-real time.
Conmed (CNMD) has an AltIndex AI Score of 32/100, currently a Sell signal. The AI Score distills Conmed's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Conmed’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Conmed — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving CNMD’s AI Score?
Fundamentals
Revenue for the last quarter was $343M. This is an increase of 8.34% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 0.13%, suggesting positive year-over-year growth. Net income for the last quarter was $23M. This is an increase of 66.84% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 7.70%, suggesting positive year-over-year growth. Ebitda for the last quarter was $61M. This is an increase of 60.04% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 20.36%, suggesting positive year-over-year growth. The current P/E ratio is 24.29. This appears to be within a normal range, neither particularly high nor low.
See Conmed’s earnings and insider transactions.
Technicals
Today's stock price is $47.14. This is an increase of 0.40% compared to a month ago, indicating a positive short-term trend. Compared to a year ago, there is an increase of 4.85%, suggesting a positive long-term trend. The trend is bearish. The current SMA10 is $45.01, which is lower than the previous SMA10 of $45.03. This suggests a potential downward trend in price movement. The RSI is 47.1, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
Conmed has an estimated 142 open positions. This number is down by -9% in the last couple of months, indicating a company trying to improve its margins or cut costs. Not a great sign for a growing company. The business outlook among employees at Conmed is neutral. Conmed has an estimate of 53,000 visitors to their webpage. The number of visitors is down by -34% in the last couple of months, a worrisome trend as this can indicate a loss in customers.
Explore Conmed’s job postings, web traffic and app downloads.
Sentiment & social
Conmed has 14,000 followers on their Instagram page, with no meaningful increase or decrese in the last couple of months. Conmed has 190 followers on their Twitter page, with no meaningful increase or decrese in the last couple of months.
Track Conmed’s market sentiment.
Frequently Asked Questions: Conmed AI Stock Analysis
Conmed's AltIndex AI Score is 32/100, currently a Sell signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Conmed a Sell (32/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Conmed — company overview, fundamentals, technicals and alternative data, with a recommendation. See the CNMD AI Score or sign up to read the full thesis.
